Alpha Seven Therapeutics is focused on developing ALPHA-1062IN, which is positioned as a potential first treatment for cognitive impairment associated with mild traumatic brain injury (mTBI). The company aims to address a significant gap in the market, as the U.S. cognitive impairment market is valued at over $17 billion with no currently approved therapies. Pre-clinical data for ALPHA-1062IN has shown promising results, indicating positive cognitive effects and protective benefits for the brain without any observed toxicity in completed studies. The company holds patents for this technology that extend until 2043, highlighting its commitment to innovation in this field.

The development timeline for ALPHA-1062IN includes several key milestones, such as the completion of formulation and stability work by Q3 2024, and the anticipated acceptance of an Investigational New Drug (IND) application in the first half of 2025. Additionally, the company plans to initiate a Phase 2 clinical study in the same timeframe, with potential pathways for Fast Track designation by the second half of 2025. These steps are crucial for advancing the therapeutic candidate through the regulatory process and ultimately bringing a much-needed treatment option to market for individuals suffering from cognitive impairments due to mTBI.

United States

Licensed worldwide rights to develop and commercialize ALPHA-1062IN in TBI and related disorders from Alpha Cognition, Inc.

ALPHA-1062IN: Potential first treatment for Cognitive Impairment with Mild Traumatic Brain Injury (mTBI)

- Plans to develop and commercialize ALPHA-1062IN in TBI and related disorders

- US Cognitive Impairment in TBI market is estimated at $17B+ with no currently approved product

- ALPHA-1062IN pre-clinical data has demonstrated positive cognitive effects and protects brain from damage

- No toxicity observed in completed studies

- Patents extending to 2042

Alpha Seven Therapeutics

Company Details